ABGSC Investor Day, 8 December 2021

CEO’s presentation Annual General Meeting 2021

Redeye Diagnostics

Redeye Diagnostics 2020 (PDF)

Company presentation August 2020

Company Presentation August 2020 (PDF)

Interview with CEO Anders Rylander

Interview with CEO Anders Rylander

Company presentation May 2020

Company Presentation May 2020 (PDF)

Capital Market Day 11th of May 2020

Presentation Capital Market Day (PDF)

Nordnet Nordic Invest, Capital Markets Seminar, 6 mars 2020

Aktiedagen Lund 28 januari 

Panelsamtal: Framtidens behandling av cancer på Aktiedagen 28 januari i Lund

Pareto Securities life science analytiker går igenom Biovica 

Audiocast, December 6, 2019. Q2 Interim Report 2019/2020

Audiocast, September 19, 2019. Update on clinical development progress

Pareto Securities’ 10th Annual Health Care Conference in Stockholm 5th September 2019 

 Interview with Anders Rylander, CEO

Management presentation directed issue April 2019 

Management presentation

Web-cast telephone conference, at 09:00 am CET, March 21.

The live webcast and a recorded on-demand version including the presentation material will be accessible at: 

 Börsveckans Småbolagsdag 19 februari 2019 – intervju

 Börsveckans Småbolagsdag 19 februari 2019 – presentation

 RedEye LifeScience Dag den 21 november 2018

Biovica’s vision – ‘best-possible-treatment’ from day one

We envisage a future where every patient receives the best possible therapy from the very first day of treatment. Where medical decisions are tailored to individual needs rather than practices that work for some but not for others. Our assays will help clinicians predict and monitor response to treatment with unrivalled speed and precision. We will make ‘best-possible-treatment’ a reality.

Biovica’s mission – more informed treatment decisions

Biovica improves the way cancer is treated today regarding patient survival and quality-of-life as well as the costs borne by society. By implementing Biovica’s biomarker assays into current treatment paradigms, clinicians can make more informed decisions about medical treatment and follow-up and thereby deliver the right treatment to the right patient at the right time.